Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease

Annals of Neurology

Volumn 57, Issue 5, 2005, Pages 721-729

  Grossman, Murray ^a,b   Farmer, Jennifer ^a   Leight, Susan ^a   Work, Melissa ^a   Moore, Peachie ^a   Van Deerlin, Vivianna ^a   Pratico, Domenico ^a   Clark, Christopher M ^a   Coslett, H Branch ^a   Chatterjee, Anjan ^a   Gee, James ^a   Trojanowski, John Q ^a   Lee, Virginia M Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MORPHOMETRICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ATROPHY; BIOLOGICAL MARKERS; CEREBRAL CORTEX; COHORT STUDIES; DEMENTIA; FEMALE; FRONTAL LOBE; HUMANS; ISOPROSTANES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHENOTYPE; PROSPECTIVE STUDIES; ROC CURVE; TAU PROTEINS;

EID: 20944439059     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20477     Document Type: Article

References (38)

1. Poorkaj P, Bird TD, Wijsman EM, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 1998;43:815-825.
2. Lee VMY, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001;24:1121-1159.
3. Fabre SF, Forsell C, Viitanen M, et al. Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency but no tau gene mutations. Exp Neurol 2001;168:413-418.
4. Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lert 1999;259:133-135.
5. Mitani K, Furiya Y, Uchihara T, et al. Increased CSF tau protein in corticobasal degeneration. J Neurol 1998;245:44-46.
6. Sjogren M, Minthon L, Davidsson P, et al. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000;107:563-579.
7. Urakami K, Wada K, Arai H, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 2001;183:95-98.
8. Wallin A, Sjogren M, Blennow K, Davidsson P. Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia. Dement Geriatr Cogn Disord 2003;16:200-207.
9. McKhann G, Trojanowski JQ, Grossman M, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of a work group on frontotemporal dementia and Pick's disease. Arch Neurol 2001;58:1803-1809.
10. Maeck L, Meller J, Otto M, et al. Abeta peptide(1-42), tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia. Neurosci Lett 2002;333:33-36.
11. Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003;60:1696-1702.
12. Frank RA, Galasko D, Hampel H, et al. Biological markers for therapeutic trials in Alzheimer's disease - Proceedings of the Biological Measures Working Group: NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 2003;24:521-536.
13. Galton CJ, Patterson K, Xuereb J, Hodges JR. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging, and pathological study of 13 cases. Brain 2000;123:484-498.
14. Ikeda K, Akiyama H, Iritani S. Corticobasal degeneration with primary progressive aphasia and accentuated cortical lesion in superior temporal gyrus: case report and review. Acta Neuropathologica 1996;92:534-539.
15. Lieberman AP, Trojanowski JQ, Lee VMY, et al. Cognitive, neuroimaging, and pathologic studies in a patient with Pick's disease. Ann Neurol 1998;43:259-264.
16. Sakurai Y, Hashida H, Uesugi H. A clinical profile of corticobasal degeneration presenting as primary progressive aphasia. Eur Neurol 1996;36:134-137.
17. Turner RS, Kenyon LC, Trojanowski JQ, et al. Clinical, neuroimaging, and pathologic features of progressive non-fluent aphasia. Ann Neurol 1996;39:166-173.
18. Riley DE, Lang AE. Clinical diagnostic criteria. In: Litvan I, Goetz CG, Lang AE, eds. Corticobasal degeneration and related disorders. Philadelphia: Lippincott Williams & Wilkins, 2000: 29-34.
19. Grossman M, Ash S. Primary progressive aphasia: a review. Neurocase 2004;10:3-18.
20. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554.
21. Sjogren M, Davidsson P, Tullberg M, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:624-630.
22. Skowronsky DM, Lee VMY, Pratico D. Amyloid precursor protein and amyloid β peptide in human platelets: role of cyclooxygenase and protein kinase C. J Biol Chem 2001;276:17036-17043.
23. 2a-VI in Alzheimer's disease: correlation of a non-invasive index of lipid peroxidation with disease severity. Ann Neurol 2000;48:809-812.
24. Ashburner J, Friston K. Voxel-based morphometry: the methods. Neuroimage 2000;11:805-821.
25. Grossman M, McMillan C, Moore P, et al. What's in a name: voxel-based morphometric analyses of MRI and naming difficulty in Alzheimer's disease, frontotemporal dementia, and corticobasal degeneration. Brain 2004;127:628-649.
26. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme Medical Publishing Company, 1988.
27. Forman SD, Cohen J, Fitzgerald M, et al. Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): use of a cluster-size threshold. Magn Reson Med 1995;33:636-647.
28. Zhukareva V, Vogelsberg-Ragaglia V, Van Deerlin VMD, et al. Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Ann Neurol 2001;49:165-175.
29. Zhukareva V, Sundarraj S, Mann DM, et al. Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. Acta Neuropathologica 2003;105:469-476.
30. Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 2004;61:95-102.
31. Rosso SM, van Herpen E, Pijnenburg YAL, et al. Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. Arch Neurol 2003;60:1209-1213.
32. Chauhan A, Pirtila T, Mehta P, et al. Effect of cerebrospinal fluid from normal and Alzheimer's patients with different apolipoprotein E phenotypes on in vitro aggregation of amyloid beta-protein. J Neurol Sci 1996;141:54-58.
33. Hampel H, Goernitz A, Buerger K. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Brain Res Bull 2003;61:243-253.
34. 2a-VI differentiate AD from frontotemporal dementia. Neurology 2003;61:675-678.
35. Chan D, Fox NC, Scahill RI. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurol 2001;49:433-442.
36. Galton CJ, Patterson K, Graham KS, et al. Differing patterns of temporal atrophy in Alzheimer's disease and semantic dementia. Neurology 2001;57:216-225.
37. Halpern C, Glosser G, Clark R, et al. Dissociation of numbers and objects in corticobasal degeneration and semantic dementia. Neurology 2004;62:1163-1169.
38. Forman MS, Zhukareva V, Bergeron CB, et al. Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am J Pathol 2002;160:2045-2053.